FDA Brief

Warning letters Drugs

FDA warning letter to

Kalani AB dba Kalani Sunwear

High riskIssued Aug 6, 2025Posted Aug 12, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Kalani AB that its Sun Mousse SPF 50 sunscreen is an unapproved, misbranded drug for US sale.

What happened

On May 7, 2025, FDA reviewed Kalani's product labeling, website, Instagram and Facebook pages, where Kalani Sunwear Sun Mousse SPF 50 was offered for purchase in the United States. FDA found the product intended for use as an over-the-counter (OTC) sunscreen drug but marketed without an approved application and in a mousse/foam dosage form that no FDA order authorizes for OTC sunscreen marketing. FDA also found the label did not identify any active ingredients and that none of the listed ingredients are permitted active ingredients under the OTC sunscreen monograph.

What FDA found

  1. FDA says the sunscreen is misbranded—illegally marketed—because it is subject to section 505G but does not comply with that section and has no approved application.

    section 502(ee), FD&C Act, 21 U.S.C. 352(ee); section 505G, 21 U.S.C. 355h
  2. FDA says sunscreen in a mousse/foam dosage form may not be marketed without an approved application or a specific FDA order, and no such order exists.

    section 505G(m)(2), FD&C Act, 21 U.S.C. 355h(m)(2)
  3. FDA says the product's formulation does not meet the OTC sunscreen monograph because the label does not identify any permitted active ingredient, and the listed ingredients are not permitted active ingredients.

    OTC Monograph M020 §§ M020.10 and M020.20(a)
  4. FDA says the product is an unapproved new drug because no FDA-approved application is in effect for it.

    section 201(p), FD&C Act, 21 U.S.C. 321(p); section 505, FD&C Act, 21 U.S.C. 355
  5. FDA says introducing the misbranded drug into interstate commerce violates the law.

    section 301(a), FD&C Act, 21 U.S.C. 331(a)
  6. FDA says introducing the unapproved new drug into interstate commerce violates the law.

    section 301(d), FD&C Act, 21 U.S.C. 331(d)

What FDA wants

FDA asks Kalani to respond in writing within 15 working days of receiving the letter, describing corrective steps, how it will prevent recurrence, and related documentation; if it disagrees, it must give reasoning and supporting information.

Who should pay attention

  • U.S. retailers and e-commerce sellers of imported sunscreens
  • brands using mousse or foam sunscreen formats
  • companies using EU UV filters in U.S. sunscreen products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk